Smith & Nephew withdraw 185 BHR (Birmingham Hip Resurfacing) implants:
This article was originally published in Clinica
Smith & Nephew has recalled 185 of its Birmingham Hip Resurfacing system after discovering that the implants had been incorrectly packaged by the subcontractor. The mistake led to different sized acetabular cups being mixed together. S&N said the error was limited to a small number of batches and that several implants have already been recovered in their packaging. The company added that it has warned, or is in the process of warning, all hospitals that have received the implants and are -working closely" with surgeons and patients on the appropriate corrective action. The UK and US regulatory authorities have also been notified about the recall.
You may also be interested in...
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.
COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the ‘paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.